- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04015180
Extension Study to Evaluate the Long-term Outcomes of Subjects in Study 20090 (FIREFLEYE next)
An Extension Study to Evaluate the Long-term Outcomes of Subjects Who Received Treatment for Retinopathy of Prematurity in Study 20090
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Actual)
Phase
- Phase 3
Contacts and Locations
Study Locations
-
-
-
San Juan, Argentina, 5400
- Hospital Público Descentralizado "Dr. Guillermo Rawson"
-
-
-
-
-
Brugge, Belgium, 8000
- AZ Sint-Jan Brugge-Oostende | Sint-Jan - Cardiology
-
-
-
-
-
Sao Paulo, Brazil, 04023-061
- Unifesp/Epm
-
-
Sao Paulo
-
Botucatu, Sao Paulo, Brazil, 18618 970
- Hospital das Clínicas de Botucatu - UNESP Botucatu
-
-
-
-
-
Plovdiv, Bulgaria, 4002
- UMHAT Sveti Georgi
-
Sofia, Bulgaria, 1407
- Acibadem City Clinic Multiprofile Hospital for Active Treatm
-
Sofia, Bulgaria, 1619
- Spec. Hospital of Ophthalm. for Active Treatment Visus
-
Varna, Bulgaria, 9000
- Spec. Hosp. of Ophthalm. Disease for Active Treatment Varna
-
-
-
-
-
Ostrava, Czechia, 708 52
- Fakultni Nemocnice Ostrava
-
Praha 2, Czechia, 12808
- Vseobecna fakultni nemocnice v Praze
-
-
-
-
-
Athens, Greece, 11527
- P & A KYRIAKOU Children's Hospital
-
Ioannina, Greece, 45500
- University General Hospital of Ioannina
-
Thessaloniki, Greece, 56403
- Papageorgiou General Hospital of Thessaloniki
-
-
-
-
-
Budapest, Hungary, 1125
- EKBC, Uj Szent Janos Korhaz es Szakrendelo
-
-
-
-
-
Rehovot, Israel, 7661041
- Kaplan Medical Center
-
-
-
-
Lazio
-
Roma, Lazio, Italy, 00165
- IRCCS Ospedale Pediatrico Bambino Gesu
-
Roma, Lazio, Italy, 00168
- Fondazione Policlinico Universitario Agostino Gemelli Irccs
-
-
Lombardia
-
Milano, Lombardia, Italy, 20122
- Fondazione Irccs Ca' Granda Ospedale Maggiore Policlinico
-
-
Umbria
-
Perugia, Umbria, Italy, 06129
- A.O. di Perugia
-
-
-
-
-
Fukuoka, Japan, 812-8582
- Kyushu University Hospital
-
Fukuoka, Japan, 814-0180
- Fukuoka University Hospital
-
Fukushima, Japan, 960-1295
- Fukushima Medical University Hospital
-
-
Fukuoka
-
Kitakyushu, Fukuoka, Japan, 807-8556
- Hospital of the University of Occupational and Environmental Health, Japan
-
Kurume, Fukuoka, Japan, 830-0011
- Kurume University Hospital
-
-
Okinawa
-
Shimajiri-gun, Okinawa, Japan, 901-1193
- Okinawa Prefectural Nanbu Medical Center and Children's MC
-
-
Osaka
-
Osakasayama, Osaka, Japan, 589-8511
- Kindai University Hospital
-
-
Tokyo
-
Fuchu, Tokyo, Japan, 183-8561
- Tokyo Metropolitan Hospital Organization Tokyo Metropolitan Children's Medical Center
-
Sumida-ku, Tokyo, Japan, 130-8575
- Tokyo Metropolitan Bokutoh Hospital
-
Toshima-ku, Tokyo, Japan, 170-8476
- Tokyo Metropolitan Ohtsuka Hospital
-
-
-
-
-
Seoul, Korea, Republic of, 138-736
- Asan Medical Center
-
-
Chungcheongnamdo
-
Cheonan, Chungcheongnamdo, Korea, Republic of, 31151
- Soon Chun Hyang University Cheonan Hospital
-
-
-
-
-
Kuala Lumpur, Malaysia, 50586
- Hospital Kuala Lumpur
-
-
-
-
-
Veldhoven, Netherlands, 5504 DB
- Maxima Medisch Centrum, locatie Veldhoven
-
-
-
-
-
Lisboa, Portugal, 1449-005
- Centro Hospitalar de Lisboa Ocidental | Clin Res Dept
-
-
Lisboa
-
Amadora, Lisboa, Portugal, 2720-276
- Hospital Prof. Dr. Fernando Fonseca
-
-
-
-
-
Iasi, Romania, 700038
- Spitalul Clinic de Obstretica si Ginecologie "Cuza Voda"
-
-
Cluj
-
Cluj-Napoca, Cluj, Romania, 400006
- Clinical Emergency County Hospital
-
-
-
-
-
Kaluga, Russian Federation, 248007
- FSAI NMRC IRTC "Eye Microsurgery", Kaluga's Branch
-
Moscow, Russian Federation, 119620
- FGBUZ "NPC of special children care n.a. Voino-Yaseneckogo"
-
Saint-Petersburg, Russian Federation, 198205
- City Children Hospital ¿1
-
-
-
-
-
Singapore, Singapore, 229899
- KK Women's and Children's Hospital
-
-
-
-
-
Bratislava, Slovakia, 833 41
- Narodny ustav detskych chorob
-
-
-
-
-
Madrid, Spain, 28041
- Hospital Universitario 12 de Octubre
-
Madrid, Spain, 28046
- Hospital la Paz - oftalmologia
-
-
Málaga
-
Malaga, Málaga, Spain, 29010
- Hospital Regional de Malaga | Oftalmologia
-
-
-
-
-
Göteborg, Sweden
- Sahlgrenska Universitetssjukhuset
-
-
-
-
-
Taipei, Taiwan, 10449
- Mackay Memorial Hospital
-
-
Kaohsiung
-
Kaohsiung City, Kaohsiung, Taiwan, 807377
- Kaohsiung Medical University Chung-Ho Memorial Hospital
-
-
-
-
-
Ankara, Turkey, 06100
- Hacettepe Universitesi Tip Fakultesi
-
Ankara, Turkey, 06500
- Gazi Universitesi Tip Fakultesi
-
Antalya, Turkey, 07100
- Saglik Bilimleri Universitesi Antalya EA Hastanesi
-
Eskisehir, Turkey, 26480
- Eskisehir Osmangazi Universitesi Tip Fakultesi
-
Yüregir, Turkey, 1370
- S.B.U. Adana Sehir Egitim ve Arastirma Hastanesi
-
-
-
-
-
Odesa, Ukraine, 65061
- The Filatov Institute of Eye Diseases and Tissue Therapy
-
-
-
-
-
Birmingham, United Kingdom, B15 2TG
- Birmingham Womens Hospital
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Subject was treated in Study 20090
- Age less than 13 months of chronological age
- Signed informed consent from parent(s)/legally authorized representative(s), which includes compliance with the requirements and restrictions listed in the informed consent form (ICF) and in this protocol
Exclusion Criteria:
- Subject has a condition preventing participation in the study, or performance of study procedures.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Other
- Allocation: Non-Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Aflibercept arm
No study treatment will be administered.
The treatments to be evaluated in this study were administered in Study 20090.
|
Treatment administered in 20090.
Solution in a sterile glass vial, Dose A, IVT injection.
|
Active Comparator: Laser photocoagulation arm
No study treatment will be administered.
The treatments to be evaluated in this study were administered in Study 20090.
|
Treatment administered in 20090.
Transpupillary conventional laser ablative therapy
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Binocular best-corrected visual acuity in Snellen equivalent
Time Frame: At 5 years of age.
|
At 5 years of age.
|
|
Proportion of subjects with ocular AEs and SAEs
Time Frame: Up to 5 years of age.
|
AE: adverse event SAE: serious adverse event
|
Up to 5 years of age.
|
Proportion of subjects with systemic AEs and SAEs
Time Frame: Up to 5 years of age.
|
Up to 5 years of age.
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Proportion of subjects developing unfavorable ocular structural outcome
Time Frame: At 1,3 and 5 years of age.
|
Unfavorable ocular structural outcome include: retinal detachment, macular dragging, macular fold, retrolental opacity |
At 1,3 and 5 years of age.
|
Proportion of subjects with absence of active ROP and unfavorable structural outcomes
Time Frame: At 1 year of age.
|
At 1 year of age.
|
|
Best-corrected visual acuity in each eye
Time Frame: At 3 and 5 years of age.
|
At 3 and 5 years of age.
|
|
Refractive spherical equivalent in each eye
Time Frame: At 3 and 5 years of age
|
At 3 and 5 years of age
|
|
Neurodevelopmental outcomes using BSID-III
Time Frame: At 2 years of age
|
BSID-III: The Bayley Scales of Infant and Toddler Development, Third Edition (BSID-III) is a standard series of tests that will assess the development of children in 3 areas: cognition, language, and motor skills.
It is recommended to be assessed at screening, 1 year and 2 years of age.
The assessment at 2 years of age is mandatory.
|
At 2 years of age
|
Neurodevelopmental outcomes using WPPSI-IV
Time Frame: At 5 years of age
|
WPPSI-IV: The Wechsler Preschool and Primary Scale of Intelligence, Fourth Edition is designed to assess development of older children and is recommended to be performed at 3, 4 and 5 years of age.
The assessment at 5 years of age is mandatory.
In cases where the WPSSI-IV cannot be used, the Differential Ability Scales II (DAS-II) may be used as an alternative.
|
At 5 years of age
|
Neurodevelopmental outcomes using VABS-II
Time Frame: At 2 and 5 years of age
|
VABS-II: Vineland Adaptive Behavior Scales, Second Edition Expanded Interview will be included, which includes 4 areas: Communication, Daily Living skills, Socialization and Motor Skills.
It is recommended to be assessed at 2, 3, 4 and 5 years of age.
The assessments at 2 years and 5 years of age are mandatory.
|
At 2 and 5 years of age
|
Proportion of subjects with recurrence of ROP
Time Frame: At 3 and 5 years of age.
|
At 3 and 5 years of age.
|
|
Proportion of subjects requiring treatment for ROP
Time Frame: Up to 5 years of age.
|
Up to 5 years of age.
|
|
Proportion of subjects requiring ophthalmological treatment
Time Frame: Up to 5 years of age.
|
Up to 5 years of age.
|
Collaborators and Investigators
Sponsor
Collaborators
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Eye Diseases
- Infant, Newborn, Diseases
- Pregnancy Complications
- Obstetric Labor Complications
- Obstetric Labor, Premature
- Infant, Premature, Diseases
- Female Urogenital Diseases and Pregnancy Complications
- Urogenital Diseases
- Retinal Diseases
- Premature Birth
- Retinopathy of Prematurity
- Physiological Effects of Drugs
- Antineoplastic Agents
- Angiogenesis Inhibitors
- Angiogenesis Modulating Agents
- Growth Substances
- Growth Inhibitors
- Aflibercept
Other Study ID Numbers
- 20275
- 2018-003180-54 (EudraCT Number)
- 2023-504207-89-00 (Other Identifier: CTIS (EU))
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
Availability of this study's data will later be determined according to Bayer's commitment to the EFPIA/PhRMA "Principles for responsible clinical trial data sharing". This pertains to scope, timepoint and process of data access. As such, Bayer commits to sharing upon request from qualified researchers patient-level clinical trial data, study-level clinical trial data, and protocols from clinical trials in patients for medicines and indications approved in the US and EU as necessary for conducting legitimate research. This applies to data on new medicines and indications that have been approved by the EU and US regulatory agencies on or after January 01, 2014.
Interested researchers can use www.vivli.org to request access to anonymized patient-level data and supporting documents from clinical studies to conduct research. Information on the Bayer criteria for listing studies and other relevant information is provided in the member section of the portal.
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Retinopathy of Prematurity (ROP)
-
University Hospital FreiburgWithdrawn
-
Novartis PharmaceuticalsCompletedRetinopathy of Prematurity (ROP)United States, Austria, Belgium, Croatia, Czechia, Denmark, Egypt, France, Germany, Greece, Hungary, India, Italy, Japan, Malaysia, Romania, Russian Federation, Saudi Arabia, Slovakia, Taiwan, Turkey, United Kingdom, Lithuania, Estonia
-
ShireCompletedRetinopathy of Prematurity (ROP)United States, Italy, Netherlands, Poland, Sweden, United Kingdom
-
NICHD Neonatal Research NetworkEunice Kennedy Shriver National Institute of Child Health and Human Development... and other collaboratorsTerminatedRetinopathy of Prematurity (ROP)United States
-
BayerRegeneron PharmaceuticalsCompletedAflibercept for Retinopathy of Prematurity - Intravitreal Injection Versus Laser Therapy (FIREFLEYE)Retinopathy of Prematurity (ROP)Spain, Singapore, Hong Kong, Korea, Republic of, Malaysia, Japan, Taiwan, Sweden, Portugal, Belgium, Argentina, Bulgaria, Italy, Austria, Brazil, Czechia, Greece, Hungary, Israel, Netherlands, Poland, Romania, Russian Federation, Slov... and more
-
University Hospital FreiburgCompletedRetinopathy of Prematurity (ROP)Germany
-
ShireCompletedRetinopathy of Prematurity (ROP)United States, Italy, Netherlands, United Kingdom, Sweden, Poland
-
Georgetown UniversityCompleted
-
Baylor College of MedicineCompleted
-
Siloam VisionNational Eye Institute (NEI)Recruiting
Clinical Trials on Eylea (Aflibercept, BAY86-5321)
-
BayerCompleted
-
BayerRegeneron PharmaceuticalsRecruitingMacular Edema Secondary to Retinal Vein OcclusionJapan, Korea, Republic of, China, Israel, Lithuania, United States, Italy, Spain, Hungary, Portugal, Serbia, Poland, United Kingdom, Thailand, Czechia, Austria, Germany, Turkey, Australia, Bulgaria, Estonia, France, Georgia, Latvia, Mal... and more
-
BayerRegeneron PharmaceuticalsActive, not recruitingNeovascular Age-Related Macular DegenerationUnited States, Spain, Korea, Republic of, Czechia, Japan, Singapore, China, Serbia, Lithuania, Taiwan, Australia, Estonia, Austria, Israel, France, Italy, Switzerland, Slovakia, Ukraine, Bulgaria, Portugal, Latvia, Canada, Hungary, Arge... and more
-
BayerCompleted
-
BayerRegeneron PharmaceuticalsCompleted
-
BayerCompleted
-
BayerRegeneron PharmaceuticalsTerminatedNeovascular (Wet) Age-related Macular DegenerationCanada, United Kingdom
-
Regeneron PharmaceuticalsBayerCompletedNeovascular (Wet) Age-Related Macular DegenerationUnited States, Puerto Rico
-
BayerRegeneron PharmaceuticalsCompletedWet Age-related Macular DegenerationSwitzerland
-
BayerRecruitingRetinopathy of Prematurity | Newborns | InfantsJapan